IRONWOOD PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Other Comprehensive Income (Loss), Net of Tax of $471.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $471.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was $265.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $312.00K.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$2.32M, a 613.27% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $3.95M.
- IRONWOOD PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was -$3.03M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $471.00K 10-Q · filed 2026-08-06 | $736.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $265.00K 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | $312.00K 10-Q · filed 2025-11-10 | -$2.01M derived: sum of 2 quarters · filed 2026-08-06 | -$2.64M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$2.32M 10-Q · filed 2026-08-06 | -$2.95M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$629.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $3.95M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$1.58M 10-Q · filed 2025-11-10 | -$1.13M derived: sum of 2 quarters · filed 2025-11-10 | $979.00K derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $452.00K 10-Q · filed 2025-11-10 | $2.56M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.11M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | -$3.03M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$771.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |